Structured evidence table for Phosphatidylcholine Cognition Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Phosphatidylcholine Cognition Randomized Trial | This narrative review summarizes current preclinical and clinical evidence regarding the mechanistic and clinical relevance of L-α-GPC in neurodegenerative disorders associated with cognitive impairment. | 4 | Putri VA (2026) | L-α-GPC in Cognitive Decline: Mechanisms and Clinical Evidence in Neurodegenerative Disorders. |
| Phosphatidylcholine Cognition Randomized Trial | In animal models, L-α-GPC has been associated with improved cognitive performance, reduced neuroinflammation, and attenuation of amyloid-β and tau-related pathological features. | 4 | Putri VA (2026) | L-α-GPC in Cognitive Decline: Mechanisms and Clinical Evidence in Neurodegenerative Disorders. |
| Phosphatidylcholine Cognition Randomized Trial | However, the interpretation of these findings should be cautious because the available evidence remains heterogeneous, with notable variability in study design, dosage regimens, treatment duration, and outcome measures. | 4 | Putri VA (2026) | L-α-GPC in Cognitive Decline: Mechanisms and Clinical Evidence in Neurodegenerative Disorders. |
| Phosphatidylcholine Cognition Randomized Trial | Neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), and vascular dementia are characterized by progressive neuronal loss, synaptic dysfunction, and cognitive decline. | 4 | Putri VA (2026) | L-α-GPC in Cognitive Decline: Mechanisms and Clinical Evidence in Neurodegenerative Disorders. |
| Phosphatidylcholine Cognition Randomized Trial | However, its metabolite trimethylamine N-oxide is considered a potential cardiovascular risk factor. | 4 | Wang W (2026) | Association between egg-derived phosphatidylcholine intake and trimethylamine N-oxide in healthy middle-aged and older adults. |
| Phosphatidylcholine Cognition Randomized Trial | RESULTS: In the high-dose phosphatidylcholine group, serum trimethylamine N-oxide concentration increased significantly at 12 weeks (Week 12) compared with Baseline (Week 0) (P = 0.028). | 4 | Wang W (2026) | Association between egg-derived phosphatidylcholine intake and trimethylamine N-oxide in healthy middle-aged and older adults. |
| Phosphatidylcholine Cognition Randomized Trial | Across all groups, mean trimethylamine N-oxide values remained substantially below the threshold associated with high clinical risk. | 4 | Wang W (2026) | Association between egg-derived phosphatidylcholine intake and trimethylamine N-oxide in healthy middle-aged and older adults. |
| Phosphatidylcholine Cognition Randomized Trial | BACKGROUND: Egg-derived phosphatidylcholine may support the maintenance of cognitive function. | 4 | Wang W (2026) | Association between egg-derived phosphatidylcholine intake and trimethylamine N-oxide in healthy middle-aged and older adults. |
Source documents